Journal of the Practice of Cardiovascular Sciences

REVIEW ARTICLE
Year
: 2022  |  Volume : 8  |  Issue : 2  |  Page : 77--78

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure a multinational randomized trial (The EMPULSE Trial)


Souvik Sardar 
 Department of Cardiology, AIIMS, New Delhi, India

Correspondence Address:
Souvik Sardar
Department of Cardiology, AIIMS, New Delhi
India

The EMPULSE trial was a randomized, double-blind, intention-to-treat trial that screened 566 patients, hospitalized for acute heart failure (HF). It showed that empagliflozin is effective and safe in patients admitted as decompensated chronic HF or de novo HF irrespective of baseline ejection fraction (EF).


How to cite this article:
Sardar S. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure a multinational randomized trial (The EMPULSE Trial).J Pract Cardiovasc Sci 2022;8:77-78


How to cite this URL:
Sardar S. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure a multinational randomized trial (The EMPULSE Trial). J Pract Cardiovasc Sci [serial online] 2022 [cited 2022 Sep 26 ];8:77-78
Available from: https://www.j-pcs.org/article.asp?issn=2395-5414;year=2022;volume=8;issue=2;spage=77;epage=78;aulast=Sardar;type=0